These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 29243329

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M, Kato M, Koh K, Hanada R.
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M, Sakamoto Y, Sato T.
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [Abstract] [Full Text] [Related]

  • 25. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S, Perera M, Fernández-Fuertes F, Ríos de Paz MA, Torres M, Raya JM, Hernández MT.
    Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M.
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [Abstract] [Full Text] [Related]

  • 29. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L, Enríquez H, Esteve J, Cervera R, Espinosa G.
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. What is publication? The case of eltrombopag.
    Benham L, Guo L, Turner R.
    Lancet; 2011 Jan 29; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract] [Full Text] [Related]

  • 35. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
    Makar RS, Zhukov OS, Sahud MA, Kuter DJ.
    Am J Hematol; 2013 Dec 29; 88(12):1041-4. PubMed ID: 23913253
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Thrombopoietin receptor agonists: ten years later.
    Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB.
    Haematologica; 2019 Jun 29; 104(6):1112-1123. PubMed ID: 31073079
    [Abstract] [Full Text] [Related]

  • 38. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
    Ghadaki B, Nazi I, Kelton JG, Arnold DM.
    Transfusion; 2013 Nov 29; 53(11):2807-12. PubMed ID: 23451917
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.